A Phase 3 interventional study of insulin degludec/insulin aspart and insulin glargine in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 92 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-08.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 15th largest by enrollment, is one of 12 that started in 2010, is one of 49 in phase 3, and was the 7th registered.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 12 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 530 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 27 open now, 31 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 88th largest by enrollment of the 430 interventional ones that give a count, is one of 25 that started in 2010, is one of 187 in phase 3, and was the 184th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 645 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of NN5401 (insulin degludec/insulin aspart (IDegAsp)) with insulin glargine (IGlar), both as add-on to subject's ongoing treatment with metformin + at least one OAD (oral anti-diabetic drug).
The main period is registered internally at Novo Nordisk as NN5401-3590 while the extension period is registered as NN5401-3726.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
This study's enrollment of 530 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec/insulin aspart
Drug: insulin glargine
Drug pages: Insulin degludecStudies of Insulin degludecInsulin degludec pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Insulin AspartStudies of Insulin AspartInsulin Aspart pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Injected s.c. (under the skin) once daily with the breakfast meal. Dose was individually adjusted.
Injected s.c. (under the skin) once daily. Dose was individually adjusted.
Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment
Change from baseline in HbA1c after 26 weeks of treatment.
Time frame: Week 0, Week 26
Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes
Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.
Time frame: Week 0 to Week 53 + 7 days follow up
Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes
Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.
Time frame: Week 0 to Week 53 + 7 days follow up
Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs)
Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild:no or transient symptoms, no interference with the subject's daily activities. Moderate: marked symptoms, moderate interference with the subject's daily activities. Severe: considerable interference with the subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalisation/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect
Time frame: Week 0 to Week 53 + 7 days follow up
Extension Trial (Secondary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment
Change from baseline in HbA1c after 52 weeks of treatment.
Time frame: Week 0, Week 53
Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 26
Mean of SMPG at 26 weeks of treatment. Plasma glucose measured: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime, at 4 am and before breakfast.
Time frame: Week 26
The trial was conducted at 88 sites in 8 countries: Austria (4), India (7), South Korea (5), Poland (6), Russia (10), Spain (11), Turkey (5), and United States of America (40). Some sites did not enroll subjects in the extension period.
| Milestone | IDegAsp OD | IGlar OD |
|---|---|---|
| Started | 266 | 264 |
| Exposed | 265 | 261 |
| Completed | 219 | 232 |
| Not completed | 47 | 32 |
| Withdrew: Adverse event | 5 | 3 |
| Withdrew: Lack of efficacy | 4 | 2 |
| Withdrew: Protocol violation | 6 | 5 |
| Withdrew: Withdrawal criteria | 22 | 11 |
| Withdrew: Unclassified | 10 | 11 |
| Milestone | IDegAsp OD | IGlar OD |
|---|---|---|
| Started | 192 | 221 |
| Completed | 179 | 209 |
| Not completed | 13 | 12 |
| Withdrew: Adverse event | 3 | 3 |
| Withdrew: Protocol violation | 2 | 3 |
| Withdrew: Withdrawal criteria | 2 | 1 |
| Withdrew: Unclassified | 6 | 5 |
Change from baseline in HbA1c after 26 weeks of treatment.
| percentage of glycosylated haemoglobin | IDegAsp OD | IGlar OD |
|---|---|---|
| Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment | -1.65 ± 1.28 | -1.72 ± 1.17 |
Change from baseline in HbA1c after 52 weeks of treatment.
| percentage of glycosylated haemoglobin | IDegAsp OD | IGlar OD |
|---|---|---|
| Extension Trial (Secondary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment | -1.39 ± 1.23 | -1.34 ± 1.16 |
Mean of SMPG at 26 weeks of treatment. Plasma glucose measured: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime, at 4 am and before breakfast.
| mmol/L | IDegAsp OD | IGlar OD |
|---|---|---|
| Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 26 | 7.9 ± 2.1 | 7.9 ± 1.7 |
Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.
| Episodes/100 years of patient exposure | IDegAsp OD | IGlar OD |
|---|---|---|
| Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes | 419 | 211 |
Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.
| Episodes/100 years of patient exposure | IDegAsp OD | IGlar OD |
|---|---|---|
| Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes | 19 | 53 |
Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild:no or transient symptoms, no interference with the subject's daily activities. Moderate: marked symptoms, moderate interference with the subject's daily activities. Severe: considerable interference with the subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalisation/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect
| Events/100 years of patient exposure | IDegAsp OD | IGlar OD |
|---|---|---|
| Adverse events (AE) | 313 | 238 |
| Serious AE | 17 | 9 |
| Severe AE | 9 | 10 |
| Moderate AE | 77 | 66 |
| Mild AE | 227 | 162 |
| Fatal AE | 2 | 1 |
Collected over Week 0 to Week 53 + 7 days follow up.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDegAsp OD | — | 30/265 (11.3%) | 88/265 (33.2%) |
| IGlar OD | — | 15/261 (5.7%) | 79/261 (30.3%) |
| Event | IDegAsp OD | IGlar OD |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 2/265 | 0/261 |
| Hypoglycaemic unconsciousnessMetabolism and nutrition disorders | 2/265 | 1/261 |
| Duodenal Ulcer HaemorrhageGastrointestinal disorders | 2/265 | 0/261 |
| Myocardial infarctionCardiac disorders | 2/265 | 0/261 |
| Ileus paralyticGastrointestinal disorders | 0/265 | 1/261 |
| Bile duct stoneHepatobiliary disorders | 0/265 | 1/261 |
| CholelithiasisHepatobiliary disorders | 1/265 | 1/261 |
| Skull fractureInjury, poisoning and procedural complications | 0/265 | 1/261 |
| Renal colicRenal and urinary disorders | 0/265 | 1/261 |
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 0/265 | 1/261 |
| Event | IDegAsp OD | IGlar OD |
|---|---|---|
| NasopharyngitisInfections and infestations | 36/265 | 35/261 |
| HypertensionVascular disorders | 20/265 | 11/261 |
| HeadacheNervous system disorders | 16/265 | 11/261 |
| Back PainMusculoskeletal and connective tissue disorders | 16/265 | 11/261 |
| DiarrhoeaGastrointestinal disorders | 13/265 | 15/261 |
| Upper Respiratory Tract InfectionInfections and infestations | 15/265 | 12/261 |
| BronchitisInfections and infestations | 14/265 | 10/261 |
Baseline characteristics for all the randomised subjects (the full analysis set \[FAS\]) were collected at the beginning of main trial. One subject was excluded from FAS because the subject was randomised in error and was not dosed.
| Age, Continuous(years) | IDegAsp OD | IGlar OD | Total |
|---|---|---|---|
| Mean | 57.4 ± 9.0 | 56.4 ± 9.2 | 56.9 ± 9.1 |
| Gender(Participants) | IDegAsp OD | IGlar OD | Total |
|---|---|---|---|
| Female | 141 | 127 | 268 |
| Male | 125 | 136 | 261 |
| Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin) | IDegAsp OD | IGlar OD | Total |
|---|---|---|---|
| Mean | 8.9 ± 1.0 | 8.9 ± 0.9 | 8.9 ± 0.9 |
| Fasting plasma glucose (FPG)(mmol/L) | IDegAsp OD | IGlar OD | Total |
|---|---|---|---|
| Mean | 10.1 ± 2.9 | 10.4 ± 2.8 | 10.2 ± 2.9 |
The record gives a start of Jan 2010, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 5 years 1 month after primary completion. A results delay was requested in Feb 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Insulin Aspart · Insulin Glargine